EXPERTS EXAMINING LINKS between the AstraZeneca vaccine and blood clots have found no specific risk factors, including age, but are carrying out further analysis, the EU’s drug regulator said today.
“At present the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events,” the Amsterdam-based EMA said in a statement.The EMA statement came after experts met on Monday to discuss their latest findings on the AstraZeneca vaccine. Their comments will be discussed at the safety committee’s meeting next week.
Related Reads 31.03.21 'This will benefit everyone': Health Minister suggests new vaccine plan may allow quicker reopening of society 31.03.21 'Sucker punch': Unions criticise new vaccine strategy but Varadkar says decision based 'on the science' 31.03.21 Number of people hospitalised with Covid-19 drops to lowest number since late December
“We plan to submit these data to FDA as a proposed amendment to our emergency use authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.” “It is very important to enable them to get back to everyday school life and to meet friends and family while protecting them and their loved ones.”